Skip to NavigationSkip to content

Gilead's CAR-T therapy Yescarta now available via NHS Scotland for two forms of B-cell lymphoma

Published on 08/10/19 at 10:56am

News has broken that the Scottish Medicines Consortium (SMC) has chosen to approve the use of Gilead’s chimeric antigen receptor T cell (CAR-T) therapy Yescarta (axicabtagene ciloleucel) on the NHS in Scotland.

Following the decision, patients will be able to receive the therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), in adult patients who have tried two or more lines of systemic therapy.

The ruling marks the second NHS approval of a CAR-T therapy in Scotland, following Novartis’ Kymriah (tisagenlecleucel) earlier this year for the treatment of relapsed/refractory DLBCL in adults and acute lymphoblastic leukaemia.

“This is further good news for people affected by lymphoma as it means there is wider access to CAR T cell therapy in Scotland. It is important for people affected by DLBCL and particularly significant for people affected by primary mediastinal B-cell lymphoma, for whom CAR T cell therapy would not otherwise be available in Scotland,” remarked Stephen Scowcroft, Director of Operations and External Affairs at Lymphoma Action.

General Manager, Gilead UK & Ireland’s General Manager Hilary Hutton-Squire also remarked: “This is an important day for patients in Scotland with certain aggressive forms of blood cancer. Yescarta is an individualised cell therapy that provides a valuable treatment option for patients who have exhausted other therapies, meaning they may have just months left to live, potentially changing their outcomes.” 

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches